U.S. NIAID-sponsored trial will evaluate heterologous booster regimens, including NVX-CoV2373, after primary series with current USFDA approved or emergency use authorized-vaccines
High level of vaccine efficacy maintained over a 6-month period of surveillance
The first wave of shipments includes several countries, such as Germany, France and Austria
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Canada
Immune responses were about two-to-three-fold higher in adolescents than in adults against all variants studied. Vaccine was well-tolerated with no safety signals identified
It would be the first protein-based alternative available in Israel
Nuvaxovid is the first protein-based Covid-19 vaccine to receive approval for provisional registration in Australia
Nuvaxovid is the first protein-based Covid-19 vaccine granted approval in South Korea
Novavax' vaccine has received authorizations of the vaccine in over 170 countries
Emergency Use Authorisation application request to be submitted following one month required by FDA EUA guidance
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)